Bronchospasmolytic Effects of Orciprenaline and Fenoterol Powder Inhalation in Anaesthetised Dogs

Traunecker, W

doi:10.1159/000194498

Cited by 2 publications

(3 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improvements in lung function in the procaterol group could be explained by several possible mechanisms. First, the bronchodilator effect of procaterol is known to be greater than that of oxitropium in vitro [7,18,19]. The lack of bronchodilator effect of the oxitropium in the present study might be attributed to its relatively weak efficacy at the tested dose [18,19].…”

Section: Discussionmentioning

confidence: 76%

“…First, the bronchodilator effect of procaterol is known to be greater than that of oxitropium in vitro [7,18,19]. The lack of bronchodilator effect of the oxitropium in the present study might be attributed to its relatively weak efficacy at the tested dose [18,19]. Recently, tiotropium, an anticholinergic agent with a much stronger action and longer duration than oxitropium, has been available for the treatment of COPD [2,20].…”

Section: Discussionmentioning

confidence: 76%

See 1 more Smart Citation

Long-term Effect of the β2-Receptor Agonist Procaterol on Daily Life Performance and Exercise Capacity in Patients with Stable Chronic Obstructive Pulmonary Disease

Shioya¹,

Satake²,

Sato

et al. 2011

Arzneimittelforschung

View full text Add to dashboard Cite

The present study was undertaken to evaluate the long-term effect of procaterol hydrochloride (CAS 62929-91-3, Meptin), a third generation beta2-receptor agonist on lung function, exercise capacity, health-related quality of life (HRQOL) and activities of daily living (ALDs) in patients with stable chronic obstructive pulmonary disease (COPD). Twenty patients were randomly assigned to the procaterol group or to the control group, who received oxitropium bromide (CAS 30286-75-0), an anticholinergic agent. Procaterol was inhaled three times a day at a dose of 20 pg, while oxitropium was inhaled three times a day at a dose of 200 microg. The subjects were evaluated based on spirometry, exercise capacity, the Borg Scale, HRQOL, and ADLs before and after 12, 24 and 52 weeks of therapy. The values of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), total lung capacity (TLC), functional residual capacity (FRC), residual volume (RV), maximal inspiratory pressure (PImax), and maximal expiratory pressure (PEmax) were significantly improved at 12, 24 and 52 weeks compared with baseline values in the procaterol group (p < 0.05, p < 0.01), while these values did not differ from baseline values at any point in the oxitropium group (p > 0.05). Additionally, 6-min walking distances and Borg Scale values showed significant improvement at 12, 24 and 52 weeks compared with baseline values in the procaterol group (p < 0.05, p < 0.01), but did not significantly differ from baseline values in the oxitropium group at any point (p > 0.05). Likewise, the scores for dyspnea, fatigue, emotional function, mastery, total scores and ADLs were significantly higher at 12, 24 and 52 weeks compared with the baseline values in the procaterol group (p < 0.05, p < 0.01), but did not differ at any point in the oxitropium group (p > 0.05). These results suggest the effectiveness of long-term regular bronchodilator therapy with the beta2-receptor agonist procaterol in patients with stable COPD.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 76%

Long-term Effect of the β2-Receptor Agonist Procaterol on Daily Life Performance and Exercise Capacity in Patients with Stable Chronic Obstructive Pulmonary Disease

Shioya¹,

Satake²,

Sato

et al. 2011

Arzneimittelforschung

View full text Add to dashboard Cite

show abstract

“…Therefore, in the present study we looked at the bronchodilating effect of OB, known to be 1.5 times more potent as a bronchodilator than ipratropium bromide and having a 30% longer duration of action than ipratropium bromide [1,17,21]. In this study three different doses of OB were administered and the bronchodilating effect was compared to placebo and fenoterol.…”

Section: Introductionmentioning

confidence: 99%

Study of the bronchodilating effect of three doses of nebulized oxitropium bromide in asthmatic preschool children using the forced oscillation technique

Pauwels

Desager

Creten

et al. 1997

European Journal of Pediatrics

View full text Add to dashboard Cite

show abstract

Bronchospasmolytic Effects of Orciprenaline and Fenoterol Powder Inhalation in Anaesthetised Dogs

Cited by 2 publications

References 3 publications

Long-term Effect of the β2-Receptor Agonist Procaterol on Daily Life Performance and Exercise Capacity in Patients with Stable Chronic Obstructive Pulmonary Disease

Long-term Effect of the β2-Receptor Agonist Procaterol on Daily Life Performance and Exercise Capacity in Patients with Stable Chronic Obstructive Pulmonary Disease

Study of the bronchodilating effect of three doses of nebulized oxitropium bromide in asthmatic preschool children using the forced oscillation technique

Contact Info

Product

Resources

About